Sona Nanotech Inc. Announces Listing On Canadian Securities Exchange

Read the original article here. Halifax, Nova Scotia, October 3, 2018 – Sona Nanotech Inc. (CSE: SONA) (“Sona” or the “Company”) is pleased to announce that the Canadian Securities Exchange (CSE) has approved the Company’s application to list its common shares on the CSE.  Effective October 4, 2018, the Company’s shares will commence trading on the CSE under the symbol “SONA”. Overview of Sona Sona is a nano technology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the research and development of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market. Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nano technologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA. The Amalgamation Pursuant to the terms of an Amalgamation, every four (4) common shares of Stockport Exploration Inc. were exchanged for one (1) common share of Sona Nanotech Ltd. (the “Sona Shares”); and every 1.5802 common shares of Sona Nanotech Ltd. were exchanged for one (1) Sona Share.  The amalgamation was completed on August 8, 2018. Stockport Exploration Inc. voluntarily delisted its common shares from the TSX Venture Exchange on August 7, 2018, and filed an application for listing its common shares on the CSE. For More Information For more information about Sona, please contact: Darren Rowles President and Chief Executive Officer Telephone: (902) 442-0653 Email: [email protected]]]>

DNA Insights Change the Injury Prevention and Rehab Industry

Athletigen teams up with CrossFit leader MobilityWOD   HALIFAX – September 17, 2018 – Athletigen Technologies, Inc. has announced the launch of its Optimum Movement and Recovery report, a DNA product that was created in partnership with Dr. Kelly Starrett and his company MobilityWOD.   The report uses 23andMe, AncestryDNA, or Athletigen DNA data, for more than 70 genetic markers to deliver 25 fundamental insights into injury risk, exercise recovery, and sleep hygiene. Customers who have already had their DNA sequenced can now use the Optimum Movement and Recovery report to gain additional knowledge about their bodies. Alternatively, if customers need a DNA kit to start their genetic journey, they can purchase one directly from Athletigen.   “It’s exciting to see people use their DNA to explore the depths of their unique human technology. Working together with Dr. Kelly and Juliet Starrett to deliver a solution that helps people make informed decisions for optimal performance and informed living has been pure joy,” says Athletigen CEO Dr. Jeremy Koenig. “It is an honour to work side by side with people who are experts in their craft and who are driven to help humans perform, feel, and live better. We want to continue to help people make decisions based on their individual bodies. This kind of interdisciplinary collaboration is essential to make this a reality for all humans.”   The Optimum Movement and Recovery report, while non-diagnostic, helps customers understand the impact of DNA on traits such as tendon and ligament injury risk, post-exercise soreness and inflammation, and sleep quality. Understanding our DNA foundation can be empowering, giving every person the ability to take charge of their health. Every person’s DNA is 99.5% the same. By understanding the 0.5% that makes each person unique, as well as the environmental factors that combine with DNA to influence athletic performance and recovery, people can make more informed lifestyle decisions daily.   MobilityWOD was founded in 2005 by Dr. Kelly Starrett and Juliet Starrett with the goal of becoming the ultimate guide to eliminating pain, preventing injury and maximizing athletic performance. MobilityWOD has grown into a leader in the CrossFit industry and has worked with high-profile clients such as the New Zealand All Blacks, UFC fighter Georges St. Pierre, actor Jason Statham, and author Tim Ferriss.   “Genetics and understanding the implication of modern genetics on my person is here to stay. It’s going to be part of the conversation,” said MobilityWOD founder Kelly Starrett. “The problem is that trying to sort through and make sense of this incredible technology is difficult, at best. So we have partnered with our friends at Athletigen to take your DNA data and translate it into actionable steps and real behaviors that can improve your life.”   Athletigen is funded by private equity investors, the Government of Canada through repayable loans from the Atlantic Canada Opportunities Agency, and the province of Nova Scotia through Nova Scotia Business Inc.   —- 30 —- Click here for a sample version of the Optimum Movement and Recovery DNA report.   Media Contact Brandon DuBreuil [email protected]   About Athletigen Athletigen is a company founded on the same performance principles that are used to help the most elite athletes in the world achieve greatness. We are driven to empower all people to understand their DNA and reach their full potential. Our mission is to help people connect their DNA data to products and services that are specific to their personal needs and are aligned with a healthful life. We achieve this through adhering to the highest scientific standards, a commitment to education, and strategic alignment with partners who embrace our passion for performance. We believe that everyone is Made for More™.   About Athletigen’s Optimum Movement and Recovery Report The new Optimum Movement and Recovery DNA report from Athletigen and MobilityWOD unlocks the power of raw DNA data files provided to every 23andMe and AncestryDNA customer with over 25 insights into injury risk, exercise recovery, and sleep hygiene. These traits include:

  • Tendon and ligament injury risk
  • Hamstring injury risk
  • Shoulder dislocation
  • Fracture risk and bone mineral density
  • Age-related strength loss
  • Post-exercise soreness and inflammation
  • Post-exercise recovery time
  • Soft tissue recovery
  • Sleep quality
  About Dr. Jeremy Koenig Dr. Jeremy Koenig, Athletigen CEO and Founder, has a background in commercializing genetic information into practical applications. Dr. Koenig was a varsity track-and-field athlete during the completion of his Ph.D. in Biochemistry and Molecular Biology at Dalhousie University in Halifax, Nova Scotia, Canada. Following graduate school, Dr. Koenig pursued postdoctoral training in human microbiome and genetics research at Cornell University. He was a Professor of Nutrigenomics, before moving to the biomedical industry to work on developing and commercializing a genetics-based fertility test. He founded Athletigen in 2014 to accelerate scientific discovery through the delivery and application of DNA to every human.   Athletigen Technologies Inc., 211 Horseshoe Lake Drive, Halifax, Nova Scotia]]>

ENTREVESTOR: Appili Names Balboni as CSO

Read the original article here.  Appili Therapeutics, a Halifax-based drug development company, has appointed its first ever Chief Scientific Officer. Armand Balboni, the new CSO, will be responsible for the company’s clinical and scientific strategy as well as steering its programs through regulatory and pre-commercialization processes. “Armand’s medical science, business, and military experience, including his particular focus in infectious disease, is a powerful combination, and having an expert of his caliber on our team is a ‘win’ for this company and our shareholders,” said Appili CEO Kevin Sullivan in a statement. Balboni has over 20 years of medical and drug development experience across an extensive range of civilian and military organizations. Early in his career, Balboni completed a period of active duty with the U.S. Army as the Deputy Director of its Office of Regulated Activities and was a senior reviewer on the clinical pharmacovigilance team. He is also a partner, senior advisor and member of the Board of Directors of the investment advisory firm Bloom Burton & Co. “Appili is doing very important work in the infectious disease space, from developing options for some of the most threatening drug-resistant bacteria emerging in our healthcare landscape, to tackling head-on significant bioterrorism threats,” Balboni said in a statement. In January, Appili struck a deal with the National Research Council of Canada to work on a vaccine that could protect people against a potential bioterror threat. The vaccine, called ATI-1701, will protect against bacteria called Francisella tularensis. The company, which is considering a listing on the Toronto Stock Exchange, has raised a total of $11.8 million in less than two years. The company is now on a fast-track to get its portfolio of anti-infectious drug candidates to market within the next couple of years. Already, Appili has had positive results from its first clinical trial in Canada and the US for its ATI-1501 drug compound. Said Balboni: “I have been impressed with their notable progress in the three years that the company has been operating, and am eager to continue supporting their efforts as the first Chief Scientific Officer.”]]>

Appili Therapeutics Appoints Veteran Drug Development Executive, Dr. Armand Balboni, as Its Inaugural Chief Scientific Officer

See the original post here. 

HALIFAX, Nova Scotia, October 1, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases, has named Dr. Armand Balboni as its first Chief Scientific Officer (CSO). In his new role with Appili, Dr. Balboni is responsible for the Company’s clinical and scientific strategy, with a particular emphasis on overseeing the scientific aspects of Appili’s government and industry collaborations and steering the Company’s clinical programs through regulatory and pre-commercialization processes.

“Armand’s medical science, business, and military experience, including his particular focus in infectious disease, is a powerful combination, and having an expert of his caliber on our team is a ‘win’ for this Company and our shareholders,” said Kevin Sullivan, MBA, Chief Executive Officer of Appili Therapeutics. “Our clinical program has grown substantially since our inception, and Armand’s experience with unique regulatory pathways and the role public/private partnerships can play in drug development will be critical to us as we advance our pipeline. We look forward to his continued guidance and support as we move into our next stage of growth.”

Dr. Balboni’s over 20-year healthcare career encompasses medical and drug development experience across a range of civilian and military organizations. He is a partner, senior advisor and member of the Board of Directors of the investment advisory firm Bloom Burton & Co. Dr. Balboni served as the senior advisor on scientific, regulatory, and medical affairs for the companies within Bloom Burton’s ‘incubation’ program, advising some of the most recent promising young Canadian biotech companies.

Earlier in his career, Dr. Balboni completed a period of active duty in the U.S. Army as the Deputy Director, Office of Regulated Activities (ORA) and senior reviewer on the clinical pharmacovigilance team. Dr. Balboni’s tenure in the ORA focused on regulatory filings (Emergency Use Authorizations (EUAs), meetings, pre-sub filings etc.) for military-relevant medical products across all therapeutic areas.

In addition, Dr. Balboni completed a U.S. Department of Defense fellowship at the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) in the Division of Anti-infective Products, and in the Office of Counterterrorism and Emerging Threats (OCET). He also served as the Chief, Office of Research and Technology Application (ORTA) at the U.S. Army Research Institute of Infectious Disease (USAMRIID). His office was tasked with oversight of all strategic partnerships between USAMRIID and universities, U.S. and foreign government agencies, and biotechnology and pharmaceutical companies.

“Appili is doing very important work in the infectious disease space, from developing options for some of the most threatening drug-resistant bacteria emerging in our healthcare landscape, to tackling head-on significant bioterrorism threats,” said Dr. Balboni. “I have been impressed with their notable progress in the three years that the Company has been operating, and am eager to continue supporting their efforts as the first Chief Scientific Officer.”

Dr. Balboni has also held various academic teaching positions, including posts at Westfield State University, the University of Maryland University College, and currently as Assistant Professor in Chemistry and Life Sciences at the United States Military Academy at West Point. He completed his doctoral work in the MD/PhD program at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School.

About Appili Therapeutics

Appili Therapeutics, Inc., was founded to advance the global fight against infectious disease by matching clearly-defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors and society face in this challenging disease space. Balancing near-to-market product candidates with higher-risk but potentially transformative early-stage programs, Appili’s growing pipeline includes assets being developed by Appili as well as an active licensing program. ATI-1501 employs Appili’s proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of pediatric and elderly patients with difficulty swallowing. ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, a novel class of antibiotics with broad-spectrum activity against Gram-negative bacteria. Via an in-licensing program, Appili acquired the rights to ATI-1701, a vaccine for tularemia, removing risk from a weaponized bioterrorism pathogen. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies. For more information, visit www.AppiliTherapeutics.com.

###

Media Relations Contact:

Mike Beyer, Sam Brown Inc. T: 312-961-2502

E: [email protected]

Investor Relations Contact:

Kimberly Stephens, CFO Appili Therapeutics

E: [email protected]

   ]]>